rivaroxaban + ticagrelor + acetylsalicylic acid

This is a combination therapy consisting of three agents: - **Rivaroxaban** is an oral direct factor Xa inhibitor anticoagulant that prevents thrombin generation and thrombus development. - **Ticagrelor** is an oral, reversible P2Y12 adenosine diphosphate (ADP) receptor antagonist that inhibits platelet activation and aggregation. - **Acetylsalicylic acid (aspirin)** is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and thereby inhibiting platelet aggregation. The combination of these drugs provides both anticoagulant and dual antiplatelet effects. It has been studied in the context of patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome, aiming to reduce the risk of cardiovascular events such as myocardial infarction, stroke, or stent thrombosis. However, this triple therapy significantly increases bleeding risk compared to dual regimens[1][6][7]. The use of all three agents together is generally reserved for select high-risk patients under close clinical supervision.